The Skin Barrier Is a Supply Chain Problem — And Most Children's Skincare Brands Are Solving for the Wrong Variable
What atopic dermatitis research can teach product founders, formulators and investors about building for outcomes, not optics.
7 min read · Founders · Investors · Product Leaders · R&D Professionals
When I started building a skincare brand for children with dry, sensitive, eczema-prone skin, I did what most founders do: I researched the market, studied the competition, and looked at what was selling. What I found wasn't surprising. It was troubling.
The dominant approach to children's sensitive skincare is, broadly, this: remove the obvious bad actors (parabens, SLS, artificial fragrance), add some shea butter or aloe vera, and put the word 'gentle' on the front. Job done.
But here's the thing. If you understand the science behind it—that is, the dermatology behind it (and actually understand it, not just the headlines)—that approach doesn't actually solve the problem. It makes the packaging more appealing while leaving the underlying biology entirely unaddressed.
That gap between what the science says and what the market delivers is where we built our brand. And I think it's a useful lens for anyone building in the health, wellness, or consumer goods space.
The Biology, Briefly
Atopic dermatitis (eczema) affects approximately 1 in 5 children in developed countries. It is not, as it is sometimes described, a simple 'sensitivity.' It is a structural failure of the skin barrier combined with an immune system that responds disproportionately to environmental inputs.
In children, the skin barrier, the stratum corneum, functions like a brick wall. Corneocytes (dead skin cells, the 'bricks') are held together by a lipid matrix (the 'mortar') composed primarily of ceramides, cholesterol and free fatty acids in a specific molar ratio of approximately 1:1:1. When this ratio is disrupted, the barrier becomes permeable: it loses water rapidly (transepidermal water loss, or TEWL) and admits allergens and microbes that would otherwise be excluded. In infants and young children, this barrier is thinner, less lipid-dense, and still developing, which makes disruptions more frequent and more severe.
In children with eczema, this disruption has a genetic origin. Loss-of-function mutations in the FLG gene (which encodes the protein filaggrin) are the single strongest known genetic risk factor for atopic dermatitis. Filaggrin is responsible for producing natural moisturising factor (NMF), the collection of amino acids, pyrrolidone carboxylic acid and urocanic acid that keeps the skin acidic and hydrated. Without adequate filaggrin, the NMF is depleted, the pH rises, and serine proteases become overactive, further degrading the very lipids the barrier depends on. It's a self-amplifying feedback loop.
"A parent who understands the skin barrier makes better purchasing decisions. A better-informed market creates better incentives for formulators. Better formulations mean fewer children in pain."
Where the Market Gets It Wrong
Most children's skincare products are formulated around symptom relief: they soothe, they hydrate, they calm. These are not bad goals. But they treat the condition as a surface problem when it is, fundamentally, a structural one (with some gut relation, but that's for another time). In a child, where the barrier is already more permeable, the gap between symptom relief and structural repair matters more, not less.
Moisturising with a water-heavy emulsion can temporarily improve the feel of dry skin. But unless that emulsion is delivering the specific lipids the barrier requires, it is not repairing the barrier. It is masking it. And a masked barrier is still a broken one. In children, that often shows up as recurring flare-ups that seem to come ‘out of nowhere,’ when in reality the barrier was never repaired.
The supply chain analogy is useful here. Imagine a logistics network with a critical failure point at warehouse level. You can improve the customer-facing delivery experience (such as faster communication or better packaging) but if the warehouse isn't functioning, you're just delaying the inevitable. The barrier is the warehouse. Most products are working on the delivery experience.
What the Science Actually Recommends
The clinical consensus reflected across pediatric dermatology, barrier biology, and lipid research is consistently clear. In children, where the skin barrier is thinner, still maturing, and frequently shaped by filaggrin-related dysfunction, these principles are not optional; they are foundational to preventing flare cycles:
• Emollients should contain physiologically relevant lipids to support barrier restoration, not just occlusion.
• Application should occur immediately post-bathing ('soak and seal'), within a three-minute window while the skin is still slightly damp, to maximize lipid penetration.
• Fragrance, including essential oils, should be avoided in children's skincare, as it is a common cause of allergic contact dermatitis.
• pH matters. A mildly acidic formulation (pH 4.5–5.5) supports natural antimicrobial peptide activity and inhibits the serine proteases that degrade the lipid matrix.
These aren't cutting-edge findings. Many of these have been established for 15–20 years. Yet the majority of products on pharmacy shelves ignore all four.
The Business Implication
For founders and investors: This represents a meaningful opportunity but only if you're willing to build for the outcome rather than the perception.
The children’s skincare market is large (with the global eczema therapeutics market projected to exceed $40 billion by 2030) and highly competitive, with a wide range of products focused primarily on symptom management rather than clinically meaningful barrier restoration. Most products compete on aesthetics, price, and brand storytelling. Very few compete on demonstrated barrier repair outcomes.
For formulators: The R&D brief is unusually clear: it requires lipids at physiological concentrations that mimic the stratum corneum, only essential and functional ingredients and zero fragrance. The hard part isn't the science; the science is settled. The hard part is communicating why this matters in a market conditioned to trust the word 'natural' over lipid concentration.
For brand builders: Your job is education. If a parent doesn't understand the biology, they cannot make an informed purchase and will default to what looks and smells trustworthy. Building that literacy in your audience is not a marketing tactic. It is your best selling product.
Why I Share This Publicly
I built P2 & You Children's Skincare because my child had eczema and I wanted a gentler approach to soothe his skin without compromise. What started as a personal frustration became a professional obsession and eventually a business.
But I also talk about it publicly - on LinkedIn, in our newsletter, in every piece of content we create - because the gap between what the science says and what most parents know is, itself, the problem. A parent who understands the skin barrier makes better purchasing decisions. A better-informed market creates better incentives for formulators. Better formulations mean fewer uncomfortable children.
That's the supply chain gap we're trying to fix. Not just the one on our shelves, but the one between science and what parents actually understand.
© 2026 Taylor C. Liddell. All rights reserved.
If you work in paediatric health, consumer goods, or brand building - I'd love to hear how you're thinking about the gap between scientific evidence and market behavior in your own space.
Sources
Andrew, P. V., Williams, S. F., Brown, K., Chittock, J., Pinnock, A., Poyner, A., Cork, M. J., & Danby, S. G. (2025). Topical supplementation with physiological lipids rebalances the stratum corneum ceramide profile and strengthens skin barrier function in adults predisposed to atopic dermatitis. British Journal of Dermatology, 193(4), 729–740. https://doi.org/10.1093/bjd/ljaf200
Bouwstra, J. A., Nădăban, A., Bras, W., McCabe, C., Bunge, A., & Gooris, G. S. (2023). The skin barrier: An extraordinary interface with an exceptional lipid organization. Progress in Lipid Research, 92, 101252. https://doi.org/10.1016/j.plipres.2023.101252
Fluhr, J. W., Muguet, V., & Christen‐Zaech, S. (2025). Restoring skin hydration and barrier function: Mechanistic Insights into basic emollients for Xerosis cutis. International Journal of Dermatology, 64(S1), 5–12. https://doi.org/10.1111/ijd.17790
Infinium Global Research - research reports, consulting, business and industry analysis. (n.d.). https://www.infiniumglobalresearch.com/market-reports/global-eczema-therapeutics-market?utm
Jaffar, H., Shakir, Z., Kumar, G., & Ali, I. F. (2022). Ichthyosis vulgaris: an updated review. Skin Health and Disease, 3(1), e187. https://doi.org/10.1002/ski2.187
Neale, H., Garza-Mayers, A. C., Tam, I., & Yu, J. (2020). Pediatric allergic contact dermatitis. Part I: Clinical features and common contact allergens in children. Journal of the American Academy of Dermatology, 84(2), 235–244. https://doi.org/10.1016/j.jaad.2020.11.002
Schoch, J. J., Anderson, K. R., Jones, A. E., Tollefson, M. M., Dermatology, S. O., Wright, T., Hunt, R., Lauren, C., Boull, C., Gupta, D., & Kenner-Bell, B. (2025). Atopic Dermatitis: Update on Skin-Directed Management: Clinical Report. PEDIATRICS, 155(6). https://doi.org/10.1542/peds.2025-071812
Stefanovic, N., & Irvine, A. D. (2023). Filaggrin and beyond. Annals of Allergy Asthma & Immunology, 132(2), 187–195. https://doi.org/10.1016/j.anai.2023.09.009
Virolainen, S. J., Satish, L., Biagini, J. M., Chaib, H., Chang, W. C., Dexheimer, P. J., Dixon, M. R., Dunn, K., Fletcher, D., Forney, C., Granitto, M., Hestand, M. S., Hurd, M., Kauffman, K., Lawson, L., Martin, L. J., Peña, L. D., Phelan, K. J., Shook, M., . . . Kottyan, L. C. (2024). Filaggrin loss-of-function variants are associated with atopic dermatitis phenotypes in a diverse, early-life prospective cohort. JCI Insight, 9(9). https://doi.org/10.1172/jci.insight.178258